Last reviewed · How we verify
autologous amniotic fluid
Autologous amniotic fluid contains growth factors, cytokines, and stem cells that promote tissue regeneration and reduce inflammation when administered therapeutically.
Autologous amniotic fluid contains growth factors, cytokines, and stem cells that promote tissue regeneration and reduce inflammation when administered therapeutically. Used for Tissue regeneration and wound healing (specific indications not well-defined in published literature).
At a glance
| Generic name | autologous amniotic fluid |
|---|---|
| Sponsor | Kasr El Aini Hospital |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine |
| Phase | FDA-approved |
Mechanism of action
Amniotic fluid is rich in bioactive molecules including growth factors (FGF, HGF, TGF-β), anti-inflammatory cytokines, and undifferentiated stem cells. When administered autologously (from the patient's own pregnancy), these components are thought to stimulate tissue repair, modulate immune responses, and promote healing in damaged tissues. The exact mechanisms remain incompletely characterized and vary by clinical application.
Approved indications
- Tissue regeneration and wound healing (specific indications not well-defined in published literature)
Common side effects
Key clinical trials
- The Collection and Application of Autologous Amniotic Fluid At Cesarean Delivery Closure. (NA)
- Efficiency of Autologous Amniotic Fluid Injection in the Healing of Cesarean Section Scar in High-Risk Population (PHASE4)
- Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases (NA)
- Efficacy Study of NuCel® in Patients Undergoing Fusion of the Lumbar Spine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- autologous amniotic fluid CI brief — competitive landscape report
- autologous amniotic fluid updates RSS · CI watch RSS
- Kasr El Aini Hospital portfolio CI